Linagliptin interactions
Full monograph for LinagliptinCheck it against another medicine
Medicines
272 documented
| Medicine | Severity | Mechanism | Effect | Sources |
|---|---|---|---|---|
| Gatifloxacin | Major | Antagonism | Gatifloxacin may interfere with the therapeutic effects of insulin and other antidiabetic agents. The use of various quinolones has been associated with… | 39 sources — open the full entry |
| Gatifloxacin + Dexamethasone | Major | Antagonism · Metabolism | Gatifloxacin may interfere with the therapeutic effects of insulin and other antidiabetic agents. The use of various quinolones has been associated with…2 documented mechanisms | 50 sources — open the full entry |
| Loteprednol Etabonate + Gatifloxacin | Major | Antagonism | Gatifloxacin may interfere with the therapeutic effects of insulin and other antidiabetic agents. The use of various quinolones has been associated with… | 39 sources — open the full entry |
| Abametapir | Moderate | Metabolism | Based on in vitro inhibition data, a single topical application of abametapir lotion may increase plasma concentrations of drugs that are substrates of CYP450… | 1 sources — open the full entry |
| Acetazolamide | Moderate | Antagonism | The efficacy of insulin and other antidiabetic agents may be diminished by certain drugs, including atypical antipsychotics, corticosteroids, diuretics… | 95 sources — open the full entry |
| Aclidinium Bromide + Formoterol Fumarate | Moderate | Antagonism | The efficacy of insulin and other antidiabetic agents may be diminished by certain drugs, including atypical antipsychotics, corticosteroids, diuretics… | 95 sources — open the full entry |
| Acyclovir + Hydrocortisone | Moderate | Antagonism | The efficacy of insulin and other antidiabetic agents may be diminished by certain drugs, including atypical antipsychotics, corticosteroids, diuretics… | 95 sources — open the full entry |
| Adenosine + Cytochrome-C + Sodium Succinate + Nicotinamide | Moderate | Antagonism | The efficacy of insulin and other antidiabetic agents may be diminished by certain drugs, including atypical antipsychotics, corticosteroids, diuretics… | 95 sources — open the full entry |
| Adrenaline | Moderate | Antagonism | The efficacy of insulin and other antidiabetic agents may be diminished by certain drugs, including atypical antipsychotics, corticosteroids, diuretics… | 95 sources — open the full entry |
| Alpelisib | Moderate | Antagonism | The efficacy of insulin and other antidiabetic agents may be diminished by certain drugs, including atypical antipsychotics, corticosteroids, diuretics… | 95 sources — open the full entry |
| Amlodipine Besilate + Benazepril Hydrochloride | Moderate | Synergy | Limited clinical data suggest that dipeptidyl peptidase IV (DPP IV) inhibitors, e.g., gliptins, have been associated with the development of angioedema, and… | 16 sources — open the full entry |
| Apalutamide | Moderate | Metabolism | Coadministration with potent inducers of the CYP450 3A4 isoenzyme and/or P-glycoprotein efflux transporter may significantly decrease the plasma concentrations… | 11 sources — open the full entry |
| Aripiprazole | Moderate | Antagonism | The efficacy of insulin and other antidiabetic agents may be diminished by certain drugs, including atypical antipsychotics, corticosteroids, diuretics… | 95 sources — open the full entry |
| Armodafinil | Moderate | Metabolism | Coadministration with potent inducers of the CYP450 3A4 isoenzyme and/or P-glycoprotein efflux transporter may significantly decrease the plasma concentrations… | 11 sources — open the full entry |
| Articaine Hydrochloride + Epinephrine Bitartrate | Moderate | Antagonism | The efficacy of insulin and other antidiabetic agents may be diminished by certain drugs, including atypical antipsychotics, corticosteroids, diuretics… | 95 sources — open the full entry |
| Asenapine Maleate | Moderate | Antagonism | The efficacy of insulin and other antidiabetic agents may be diminished by certain drugs, including atypical antipsychotics, corticosteroids, diuretics… | 95 sources — open the full entry |
| Atenolol + Chlorthalidone | Moderate | Antagonism | The efficacy of insulin and other antidiabetic agents may be diminished by certain drugs, including atypical antipsychotics, corticosteroids, diuretics… | 95 sources — open the full entry |
| Azilsartan Medoxomil + Chlorthalidone | Moderate | Antagonism | The efficacy of insulin and other antidiabetic agents may be diminished by certain drugs, including atypical antipsychotics, corticosteroids, diuretics… | 95 sources — open the full entry |
| Beclometasone + Formoterol + Glycopyrronium | Moderate | Antagonism | The efficacy of insulin and other antidiabetic agents may be diminished by certain drugs, including atypical antipsychotics, corticosteroids, diuretics… | 95 sources — open the full entry |
| Beclomethasone Dipropionate + Formoterol Fumarate | Moderate | Antagonism | The efficacy of insulin and other antidiabetic agents may be diminished by certain drugs, including atypical antipsychotics, corticosteroids, diuretics… | 95 sources — open the full entry |
| Betamethasone | Moderate | Antagonism | The efficacy of insulin and other antidiabetic agents may be diminished by certain drugs, including atypical antipsychotics, corticosteroids, diuretics… | 95 sources — open the full entry |
| Betamethasone + Calcipotriol | Moderate | Antagonism | The efficacy of insulin and other antidiabetic agents may be diminished by certain drugs, including atypical antipsychotics, corticosteroids, diuretics… | 95 sources — open the full entry |
| Betamethasone + Clotrimazole | Moderate | Antagonism | The efficacy of insulin and other antidiabetic agents may be diminished by certain drugs, including atypical antipsychotics, corticosteroids, diuretics… | 95 sources — open the full entry |
| Betamethasone + Clotrimazole + Gentamicin | Moderate | Antagonism | The efficacy of insulin and other antidiabetic agents may be diminished by certain drugs, including atypical antipsychotics, corticosteroids, diuretics… | 95 sources — open the full entry |
| Betamethasone + Neomycin Sulphate (Ophthalmic) | Moderate | Antagonism | The efficacy of insulin and other antidiabetic agents may be diminished by certain drugs, including atypical antipsychotics, corticosteroids, diuretics… | 95 sources — open the full entry |
| Betamethasone + Phenylephrine + Lignocaine | Moderate | Antagonism | The efficacy of insulin and other antidiabetic agents may be diminished by certain drugs, including atypical antipsychotics, corticosteroids, diuretics…2 documented mechanisms | 95 sources — open the full entry |
| Betamethasone Dipropionate | Moderate | Antagonism | The efficacy of insulin and other antidiabetic agents may be diminished by certain drugs, including atypical antipsychotics, corticosteroids, diuretics… | 95 sources — open the full entry |
| Betamethasone Dipropionate + Salicylic Acid | Moderate | Antagonism | The efficacy of insulin and other antidiabetic agents may be diminished by certain drugs, including atypical antipsychotics, corticosteroids, diuretics… | 95 sources — open the full entry |
| Betamethasone Sodium Phosphate | Moderate | Antagonism | The efficacy of insulin and other antidiabetic agents may be diminished by certain drugs, including atypical antipsychotics, corticosteroids, diuretics… | 95 sources — open the full entry |
| Betamethasone Valerate | Moderate | Antagonism | The efficacy of insulin and other antidiabetic agents may be diminished by certain drugs, including atypical antipsychotics, corticosteroids, diuretics… | 95 sources — open the full entry |
| Biphasic Insulin Aspart | Moderate | Synergy | Coadministration of a dipeptidyl peptidase-4 inhibitor with an insulin secretagogue (e.g., sulfonylurea, meglitinide) or insulin may potentiate the risk of… | 23 sources — open the full entry |
| Bisoprolol Fumarate + Hydrochlorothiazide | Moderate | Antagonism | The efficacy of insulin and other antidiabetic agents may be diminished by certain drugs, including atypical antipsychotics, corticosteroids, diuretics… | 95 sources — open the full entry |
| Bortezomib | Moderate | Others | Bortezomib may interfere with the therapeutic effects of insulin and other antidiabetic agents. | 11 sources — open the full entry |
| Bosentan Monohydrate | Moderate | Metabolism | Coadministration with potent inducers of the CYP450 3A4 isoenzyme and/or P-glycoprotein efflux transporter may significantly decrease the plasma concentrations… | 11 sources — open the full entry |
| Brexpiprazole | Moderate | Antagonism | The efficacy of insulin and other antidiabetic agents may be diminished by certain drugs, including atypical antipsychotics, corticosteroids, diuretics… | 95 sources — open the full entry |
| Brigatinib | Moderate | Antagonism | The efficacy of insulin and other antidiabetic agents may be diminished by certain drugs, including atypical antipsychotics, corticosteroids, diuretics… | 95 sources — open the full entry |
| Budesonide + Formoterol Fumarate | Moderate | Antagonism | The efficacy of insulin and other antidiabetic agents may be diminished by certain drugs, including atypical antipsychotics, corticosteroids, diuretics… | 95 sources — open the full entry |
| Budesonide + Glycopyrronium Bromide + Formoterol Fumarate | Moderate | Antagonism | The efficacy of insulin and other antidiabetic agents may be diminished by certain drugs, including atypical antipsychotics, corticosteroids, diuretics… | 95 sources — open the full entry |
| Bumetanide | Moderate | Antagonism | The efficacy of insulin and other antidiabetic agents may be diminished by certain drugs, including atypical antipsychotics, corticosteroids, diuretics… | 95 sources — open the full entry |
| Calcium Dobesilate + Lidocaine + Dexamethasone | Moderate | Metabolism | Coadministration with potent inducers of the CYP450 3A4 isoenzyme and/or P-glycoprotein efflux transporter may significantly decrease the plasma concentrations… | 11 sources — open the full entry |
| Candesartan Cilexetil + Hydrochlorothiazide | Moderate | Antagonism | The efficacy of insulin and other antidiabetic agents may be diminished by certain drugs, including atypical antipsychotics, corticosteroids, diuretics… | 95 sources — open the full entry |
| Captopril | Moderate | Synergy | Limited clinical data suggest that dipeptidyl peptidase IV (DPP IV) inhibitors, e.g., gliptins, have been associated with the development of angioedema, and… | 16 sources — open the full entry |
| Carbamazepine | Moderate | Metabolism | Coadministration with potent inducers of the CYP450 3A4 isoenzyme and/or P-glycoprotein efflux transporter may significantly decrease the plasma concentrations… | 11 sources — open the full entry |
| Cariprazine | Moderate | Antagonism | The efficacy of insulin and other antidiabetic agents may be diminished by certain drugs, including atypical antipsychotics, corticosteroids, diuretics… | 95 sources — open the full entry |
| Cenobamate | Moderate | Metabolism | Coadministration with potent inducers of the CYP450 3A4 isoenzyme and/or P-glycoprotein efflux transporter may significantly decrease the plasma concentrations… | 11 sources — open the full entry |
| Ceritinib | Moderate | Antagonism | The efficacy of insulin and other antidiabetic agents may be diminished by certain drugs, including atypical antipsychotics, corticosteroids, diuretics… | 95 sources — open the full entry |
| Chlorpromazine Hydrochloride | Moderate | Antagonism | The efficacy of insulin and other antidiabetic agents may be diminished by certain drugs, including atypical antipsychotics, corticosteroids, diuretics… | 95 sources — open the full entry |
| Chlorthalidone | Moderate | Antagonism | The efficacy of insulin and other antidiabetic agents may be diminished by certain drugs, including atypical antipsychotics, corticosteroids, diuretics… | 95 sources — open the full entry |
| Cinchocaine + Hydrocortisone + Framycetin + Esculin | Moderate | Antagonism | The efficacy of insulin and other antidiabetic agents may be diminished by certain drugs, including atypical antipsychotics, corticosteroids, diuretics… | 95 sources — open the full entry |
| Cinchocaine + Hydrocortisone + Neomycin + Esculin | Moderate | Antagonism | The efficacy of insulin and other antidiabetic agents may be diminished by certain drugs, including atypical antipsychotics, corticosteroids, diuretics… | 95 sources — open the full entry |
Food & lifestyle
alcohol
ModerateOthers
Alcohol may cause hypoglycemia or hyperglycemia in patients with diabetes. Hypoglycemia most frequently occurs during acute consumption of alcohol. Even modest amounts can lower blood sugar significantly, especially when the alcohol is ingested on an empty stomach or following exercise. The mechanism involves inhibition of both gluconeogenesis as well as the counter-regulatory response to hypoglycemia. Episodes of hypoglycemia may last for 8 to 12 hours after ethanol ingestion. By contrast, chronic alcohol abuse can cause impaired glucose tolerance and hyperglycemia. Moderate alcohol consumption generally does not affect blood glucose levels in patients with well controlled diabetes. A disulfiram-like reaction (e.g., flushing, headache, and nausea) to alcohol has been reported frequently with the use of chlorpropamide and very rarely with other sulfonylureas.
What to do: Patients with diabetes should avoid consuming alcohol if their blood glucose is not well controlled, or if they have hypertriglyceridemia, neuropathy, or pancreatitis. Patients with well controlled diabetes should limit their alcohol intake to one drink daily for women and two drinks daily for men (1 drink = 5 oz wine, 12 oz beer, or 1.5 oz distilled spirits) in conjunction with their normal meal plan. Alcohol should not be consumed on an empty stomach or following exercise.
10 sources
- Jerntorp P, Almer LO "Chlorpropamide-alcohol flushing in relation to macroangiopathy and peripheral neuropathy in non-insulin dependent diabetes." Acta Med Scand 656 (1981): 33-6
- Jerntorp P, Almer LO, Holin H, et al. "Plasma chlorpropamide: a critical factor in chlorpropamide-alcohol flush." Eur J Clin Pharmacol 24 (1983): 237-42
- Barnett AH, Spiliopoulos AJ, Pyke DA, et al. "Metabolic studies in chlorpropamide-alcohol flush positive and negative type 2 (non-insulin dependent) diabetic patients with and without retinopathy." Diabetologia 24 (1983): 213-5
- Hartling SG, Faber OK, Wegmann ML, Wahlin-Boll E, Melander A "Interaction of ethanol and glipizide in humans." Diabetes Care 10 (1987): 683-6
- "Product Information. Diabinese (chlorpropamide)." Pfizer U.S. Pharmaceuticals (2002):
- "Product Information. Glucotrol (glipizide)." Pfizer U.S. Pharmaceuticals (2002):
- "Product Information. Diabeta (glyburide)." Hoechst Marion-Roussel Inc, Kansas City, MO.
- Skillman TG, Feldman JM "The pharmacology of sulfonylureas." Am J Med 70 (1981): 361-72
Show all 10 sourcesShow fewer sources
- "Position Statement: evidence-based nutrition principles and recommendations for the treatment and prevention of diabetes related complications. American Diabetes Association." Diabetes Care 25(Suppl 1) (2002): S50-S60
- Cerner Multum, Inc. "UK Summary of Product Characteristics." O 0
Conditions
Conditions in which Linagliptin needs care, as documented in this source.
Pancreatitis
MajorThere have been postmarketing reports of acute pancreatitis in patients taking DPP-4 inhibitors. These drugs should be used with caution in patients with a history of pancreatitis or pancreatic disease, although it is unknown if they are at increased risk. Patients should be observed for signs and symptoms of pancreatitis during treatment. If pancreatitis is suspected, treatment should be discontinued immediately and appropriate management should be initiated.
4 sources
- "Product Information. Januvia (sitagliptin)." Merck & Co., Inc (2006):
- "Product Information. Onglyza (saxagliptin)." Bristol-Myers Squibb (2009):
- "Product Information. Tradjenta (linagliptin)." Boehringer Ingelheim (2011):
- "Product Information. Nesina (alogliptin)." Takeda Pharmaceuticals America (2013):
Therapeutic duplication
Drug classes that overlap with Linagliptin, so taking both doubles up the same effect. This source publishes no per-row citations for duplication.
incretin-based therapies
The recommended maximum number of medicines in the 'incretin-based therapies' category to be taken concurrently is usually one.Your list includes two medicines belonging to the 'incretin-based therapies' category.
Example product in the source data (US market): Insulin degludec/liraglutide
incretin-based therapies
The recommended maximum number of medicines in the 'incretin-based therapies' category to be taken concurrently is usually one.Your list includes two medicines belonging to the 'incretin-based therapies' category.
Example product in the source data (US market): Soliqua